NASDAQ: IMVTImmunovant Inc Stock Ownership - Who owns Immunovant?
Insider buying vs selling
Have Immunovant Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Atul Pande | Director | 2026-06-15 | 1,500 | $34.02 | $51.03kSell |
| Atul Pande | Director | 2026-06-15 | 1,500 | $8.43 | $12.65kBuy |
| Andrew J. Fromkin | Director | 2026-05-28 | 31,668 | $4.99 | $158.02kBuy |
| Andrew J. Fromkin | Director | 2026-05-28 | 71,492 | $7.94 | $567.65kBuy |
| Andrew J. Fromkin | Director | 2026-05-28 | 77,181 | $8.43 | $650.64kBuy |
| Andrew J. Fromkin | Director | 2026-05-28 | 16,260 | $14.70 | $239.02kBuy |
| Andrew J. Fromkin | Director | 2026-05-28 | 11,483 | $32.64 | $374.81kSell |
| Andrew J. Fromkin | Director | 2026-05-28 | 210,468 | $33.56 | $7.06MSell |
| Melanie Gloria | Chief Operating Officer | 2026-05-20 | 249 | $30.41 | $7.57kSell |
| Atul Pande | Director | 2026-05-20 | 6,000 | $8.43 | $50.58kBuy |
IMVT insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when IMVT insiders and whales buy or sell their stock.
IMVT Shareholders
What type of owners hold Immunovant Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Roivant Sciences Ltd | 55.19% | 113,317,007 | $3.79B | Insider |
| Fmr LLC | 8.25% | 16,947,888 | $566.74M | Institution |
| Deep Track Capital LP | 5.61% | 11,526,971 | $385.46M | Institution |
| Blackrock Inc | 3.20% | 6,574,497 | $219.85M | Institution |
| Baker Bros Advisors LP | 2.66% | 5,457,881 | $182.51M | Institution |
| State Street Corp | 2.21% | 4,537,929 | $151.75M | Institution |
| Tcg Crossover Management LLC | 2.17% | 4,457,988 | $149.08M | Institution |
| Morgan Stanley | 1.89% | 3,876,877 | $129.64M | Institution |
| Vanguard Portfolio Management LLC | 1.80% | 3,704,905 | $123.89M | Institution |
| Vanguard Capital Management LLC | 1.76% | 3,620,050 | $121.05M | Institution |
IMVT vs Biotech Stocks
Immunovant Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.